M. G. Vogiatzi, E. A. Macklin, F. L. Trachtenberg, E. B. Fung, A. M. Cheung, E. Vichinsky, N. Olivieri, M.Kirby, J. L. Kwiatkowski, M. Cunningham, I. A. Holm, M. Fleisher, R. W. Grady, C. M. Peterson, P. J. Giardina and Thalassemia Clinical Research Network, “Differences in the Prevalence of Growth, Endocrine and Vitamin D Abnormalities among the Various Thalassaemia Syndromes in North America,” British Journal of Haematology, Vol. 146, No. 5, pp. 546-556.

has been cited by the following article:

• TITLE: A Review of Endocrine Disorders in Thalassaemia

  AUTHORS: Parijat De, Radhika Mistry, Christine Wright, Shivan Pancham, Wyn Burbridge, Kalyan Gangopadhayay, Terence Pang, Gautam Das

  KEYWORDS: Thalassaemia; Chelation; Endocrinopathies; Diabetes; Hypothyroidism

  JOURNAL NAME: Open Journal of Endocrine and Metabolic Diseases, Vol.4 No.2, February 18, 2014

  ABSTRACT: Endocrine dysfunction in thalassaemia is amongst the most common complication and is principally attributed to excessive iron overload and suboptimal chelation. The prevalence is quite high particularly in multiethnic populations but determining the prevalence is often difficult due to the widespread heterogeneity of the population and timing of exposure to chelation therapy. Disturbances in growth, pubertal development, abnormal gonadal functions, impaired thyroid, parathyroid and adrenal functions, diabetes and disorderly bone growth are commonly encountered. Early detection and institution of appropriate transfusion regimen and chelation therapy and treatment of complications are the keys to managing this population including regular follow. In this article, we review the literature in relation to the various endocrine complications encountered in thalassaemia.